Journal
ANTI-CANCER DRUGS
Volume 33, Issue 1, Pages E622-E627Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0000000000001199
Keywords
cancer; metastasis; pyrotinib; radiotherapy
Categories
Funding
- Chongqing Science and Health Joint Project [2019QNXM027]
Ask authors/readers for more resources
This study evaluated the efficacy of Pyrotinib on HER2-positive brain metastatic breast cancer patients. The results showed that the combination of Pyrotinib and whole-brain radiotherapy significantly improved patients' treatment response rate, survival period, and duration of response, without causing additional adverse events.
Brain metastasis is a common cause of death in HER2-positive breast cancer patients. Currently, it is mainly treated by whole-brain radiotherapy. Pyrotinib is an irreversible pan-ErbB inhibitor, which has demonstrated promising tumor-suppressing activity and acceptable tolerance in previous phase trials. In the present study, we evaluated the efficacy of pyrotinib on HER2-positive brain metastatic breast cancer patients treated with whole-brain radiotherapy. A total of 20 such patients were separated into pyrotinib plus capecitabine and capecitabine-only groups in a 1:1 ratio. All patients met either the primary or secondary endpoints. Oral admission of pyrotinib together with radiotherapy can significantly increase the overall response rate, progression-free survival, time to progression and duration of response of HER2+ brain metastatic breast cancer patients, without causing extra adverse events. In addition, pyrotinib can enhance the radiosensitivity of in-vitro cultured HER2+ breast cancer cell lines. The outcome of our study suggests that pyrotinib might be an effective medication to enhance the tumor radiosensitivity of HER2-positive brain metastatic breast cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available